Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved significant revenue and profit growth in the first half of 2025, with revenue reaching 1.459 billion yuan, a year-on-year increase of 28.2%, and net profit of 156 million yuan, up 34.9% [5] - Operating cash flow for the first half of 2025 was 410 million yuan, reflecting an 84.4% year-on-year increase [5] - The company continues to expand its business model through both organic growth and acquisitions, with the integration of the acquired brand NaiRuiEr showing positive results [10] Revenue Performance - The company’s three main business segments showed strong performance: Beauty and Health Services, Medical Aesthetic Services, and Sub-health Medical Services, with respective revenues of 810 million, 500 million, and 150 million yuan, representing year-on-year growth of 29.6%, 13.0%, and 107.8% [6] - Direct sales and franchise models contributed to revenue growth, with direct sales revenue reaching 740 million yuan, up 31.0% year-on-year, and franchise revenue at 70 million yuan, up 16.2% [6] Customer Engagement - Direct sales stores saw a customer footfall of 850,000, a 48.6% increase year-on-year, and active membership grew to 112,000, up 45.7% [6] - The medical aesthetic segment also showed resilience, with foot traffic of 50,000 and active members of 24,000, reflecting year-on-year growth of 28.0% and 27.6% respectively [6] Business Expansion - The company expanded its sub-health medical services, with foot traffic reaching 19,000, a 75.5% increase, and active members growing by 93.4% [7] - The revenue from the functional medicine segment increased by 122.0% year-on-year, driven by new product lines [7] Profitability - The overall gross margin improved by 2.3 percentage points to 49.3%, and the net profit margin increased by 0.5 percentage points to 10.7% [8] - The gross margins for the three business segments were 42.1%, 56.9%, and 63.1%, with respective year-on-year increases of 1.8, 1.8, and 8.7 percentage points [9] Future Outlook - The company plans to continue its dual strategy of organic growth and acquisitions, with a focus on expanding its beauty and health brand matrix and enhancing its medical services [10] - The forecast for net profit for 2025-2027 has been adjusted upwards to 310 million, 350 million, and 410 million yuan, with corresponding EPS estimates of 1.30, 1.48, and 1.72 yuan [10]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 37.36 [1][10]. Core Insights - The company reported strong growth in its sub-health management business, with a revenue of HKD 1.459 billion for the first half of 2025, representing a year-on-year increase of 28.2%. The adjusted net profit reached HKD 191 million, up 37.8% year-on-year, with an adjusted net profit margin of 13.1% [6][10]. - The company's "Double Beauty + Double Health" business model is expected to continue benefiting from the rising consumer awareness among women and the emotional value associated with beauty and health [6][10]. - The company has received NMPA approval for several Class III medical devices for use in the medical beauty sector, and ongoing innovations in upstream research and development are expected to enhance the product offerings for downstream leading institutions [6][10]. Financial Performance - For the first half of 2025, the beauty and health services segment generated revenue of HKD 807 million, a year-on-year increase of 29.6%. The number of direct and franchise stores reached 238 and 276, respectively, with active membership in direct stores increasing by 45.7% year-on-year [7]. - The medical beauty segment reported revenue of HKD 499 million, a year-on-year increase of 13.0%, with 27 medical beauty stores and a 27.6% increase in active membership [7]. - The sub-health medical services segment saw revenue growth of 107.8% year-on-year, reaching HKD 154 million, with 11 stores and a 93.4% increase in active membership [7]. Strategic Initiatives - The company has increased its stake in Nairui'er by 20%, which is expected to enhance its market share through effective integration capabilities [8]. - A capital market value enhancement plan was initiated, focusing on long-term shareholder return mechanisms, attracting strategic investors, and implementing equity incentive plans to align management and shareholder interests [9]. Earnings Forecast and Valuation - The company maintains its earnings forecast, expecting net profits of HKD 320 million, HKD 369 million, and HKD 420 million for 2025, 2026, and 2027, respectively. The target price is set at 25x PE for 2025, reflecting the company's sustainable competitive advantages and clear long-term shareholder return mechanisms [10][19].

Core Viewpoint - Meili Tianyuan Medical Health (02373) saw its stock price rise over 5%, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, a year-on-year increase of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, reflecting a year-on-year growth of 34.9% [1] - Basic earnings per share were reported at 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, up 29.6% year-on-year [1] - Revenue from sub-health medical services reached 150 million RMB, showing a significant increase of 107.8% year-on-year [1] Market Position and Strategy - Huatai Securities highlighted that the company's evolving "dual beauty + dual health" business model is expected to benefit from the rising consumer awareness among women regarding self-care [1] - Since 2025, several Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are anticipated to enhance the product offerings of leading downstream institutions [1] - The firm maintains a buy rating on the stock, reflecting confidence in the company's growth trajectory [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373) has seen a significant stock price increase, reaching a new high of 35.06 HKD, driven by strong financial performance and market sentiment [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of 1.459 billion RMB, representing a year-on-year growth of 28.2% [1] - The profit attributable to the company's owners was 156 million RMB, up 34.9% year-on-year, with basic earnings per share of 0.68 RMB [1] - Revenue from beauty and health services amounted to 807 million RMB, reflecting a year-on-year increase of 29.6% [1] - Revenue from sub-health medical services reached 150 million RMB, showing a substantial year-on-year growth of 107.8% [1] Market Trends and Business Model - The company is benefiting from the rising consumer awareness of self-care among women, supported by its evolving "dual beauty + dual health" business model [1] - Since 2025, multiple Class III medical device products have received NMPA approval for use in the medical beauty sector, indicating ongoing innovation and regulatory support [1] - Continuous advancements in upstream research and development, including effective raw materials, photonic instruments, and AI skincare, are expected to enhance the product offerings of leading downstream institutions [1]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant revenue and profit growth, showcasing the effectiveness of its business model and strategic initiatives [1][24]. Financial Performance - Revenue for the first half of 2025 reached 1.46 billion yuan, a year-on-year increase of 28.2% [1] - Net profit rose to 170 million yuan, reflecting a substantial growth of 35.5% year-on-year [1] - Adjusted net profit was 191 million yuan, up 37.8% year-on-year, with an adjusted net profit margin of 13.1%, marking a historical high [1] - Cash and cash-equivalent assets amounted to 2 billion yuan, a 27.5% increase year-on-year, with operating cash flow of 410 million yuan, up 84.4% year-on-year [1] Business Segments - The core beauty and health services generated 810 million yuan in revenue, a 29.6% increase year-on-year, with a gross margin of 42.1% [3] - Medical beauty services achieved revenue of 500 million yuan, a 13.0% increase year-on-year, with a gross margin of 56.9% [5] - The sub-brand for sub-health medical services saw explosive growth, with revenue of 150 million yuan, a 107.8% increase year-on-year, and a gross margin of 63.1% [8] Strategic Initiatives - The company has enhanced its digital marketing and multi-channel operations, with private domain operations contributing over 46% of new memberships [5] - The acquisition of a 90% stake in the brand Nairu has shown significant integration effects, with Nairu's revenue reaching 277 million yuan and an adjusted net profit margin increasing from 6.5% to 10.4% [11] - The opening of a flagship clinic in Guangzhou, covering nearly 5,000 square meters, aims to meet the deep health and wellness needs of customers in the Greater Bay Area [14] Shareholder Structure and Market Value - The company has optimized its shareholder structure, with new significant investors enhancing strategic development [18] - A capital market value enhancement plan has been proposed, including a commitment to distribute at least 50% of annual net profit as dividends over the next three fiscal years [18] - The company's market capitalization has increased by 90% year-to-date, reflecting strong market recognition of its value [18] Business Model - The company has developed a unique "dual beauty + dual health" business model, which integrates beauty and medical services to create a competitive advantage [20] - This model allows for efficient collaboration across business segments, maximizing long-term value for members and addressing high customer acquisition costs [21] - The average annual revenue per direct store has exceeded 10 million yuan, with medical beauty and sub-health services accounting for over 45% of total revenue [22]

智通财经APP讯，美丽田园医疗健康(02373)发布截至2025年6月30日止六个月业绩，收入14.59亿元(人 民币，下同)，同比增长28.2%;公司拥有人应占溢利1.56亿元，同比增长34.9%;每股基本盈利0.68元。 会员数量增长驱动公司收入和利润再创新高。2025年上半年总收入同比增长28.2%。随着收入的稳步提 升，规模效应日益显著，推动毛利率同比提升2.3个百分点，达49.3%。 ...

美丽田园医疗健康(02373)发布截至2025年6月30日止六个月业绩，收入14.59亿元(人民币，下同)，同比 增长28.2%;公司拥有人应占溢利1.56亿元，同比增长34.9%;每股基本盈利0.68元。 会员数量增长驱动公司收入和利润再创新高。2025年上半年总收入同比增长28.2%。随着收入的稳步提 升，规模效应日益显著，推动毛利率同比提升2.3个百分点，达49.3%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於開曼群島註冊成立的有限公 司） （股份代號：2373） 截至2025年6月30日止六個月中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明綜合中期業績，連 同如下2024年同期的比較數字。該等中期業績已由審核委員會及本公司管理層審閱。 於本公告內，「我們」指本公司及倘文義另有指明，則指本集團。 | 業績概要 | | | | | --- | --- | --- | --- | | | | 截至6月30日止六個月 | | | | 2025年 | 2024年 | 變動 | | | 人民幣千元 (i) | 人民幣千元 (i) | | | | （未經審核） | （未經審核） | | | 直營門店客流 | 918,069 | 621,136 | 47.8% | ...

Group 1 - The core point of the announcement is that CPE has completed the sale of most of its shares in the company, resulting in CPE no longer being a major shareholder as of August 18, 2025 [1] - The exit of CPE is expected to significantly enhance the stability of the company's shareholder structure and release multiple positive effects, including a smoother exit for private equity fund shareholders and the introduction of diverse, high-quality long-term investors [1] - The optimization of the shareholding structure is anticipated to increase the proportion of circulating shares, thereby enhancing market liquidity [1] Group 2 - The company expresses gratitude to CPE for its strategic guidance during its development and successful market entry as an early investor [1] - Following the resignation of Mr. Hu and Mr. Geng, the board has appointed Mr. Gao and Ms. Yi as non-executive directors, effective from August 18, 2025 [2]

Core Viewpoint - The company, Meili Tianyuan Medical Health (02373), announces the completion of a significant share sale by CITIC Industrial Investment Fund Management Co., Ltd. (CPE), which has exited as a major shareholder, leading to a restructuring of the company's shareholder base and potential positive impacts on governance and market confidence [1]. Group 1 - CPE has completed the sale of most of its shares in the company as of August 18, 2025, and is no longer a major shareholder [1]. - The exit of CPE is expected to enhance the stability of the company's shareholder structure and introduce high-quality long-term investors, improving governance and boosting market confidence in the company's long-term value [1]. - The optimization of the shareholder structure is anticipated to increase the proportion of circulating shares, thereby enhancing market liquidity [1]. Group 2 - The company expresses gratitude to CPE for its strategic guidance during its development and successful market entry as an early investor [1]. - Following CPE's exit, Mr. Hu Tenghe and Mr. Geng Jiaqi have resigned from their positions as non-executive directors, effective August 18, 2025 [2]. - The board has appointed Mr. Gao Jianming and Ms. Yi Lin as non-executive directors, effective from August 18, 2025 [2].